A Four-Drug Strategy Combining Immunotherapy, Anti-Angiogenesis and Chemotherapy
Extensive-stage small cell lung cancer is an aggressive disease that can initially respond rapidly to chemotherapy but often relapses within a relatively short period.
A newer China-based treatment strategy has explored attacking the disease through three mechanisms simultaneously:
Benmelstobart + anlotinib + etoposide + carboplatin
Benmelstobart is a PD-L1 immune checkpoint inhibitor.
Anlotinib is an oral multi-target tyrosine kinase inhibitor with anti-angiogenic activity.
Etoposide and carboplatin form a standard chemotherapy backbone for extensive-stage small cell lung cancer.
The treatment therefore combines:
Chemotherapy + immunotherapy + anti-angiogenic targeted therapy
The phase III ETER701 trial evaluated this approach in previously untreated patients with extensive-stage small cell lung cancer.
Patients received benmelstobart and anlotinib together with etoposide-carboplatin during the initial treatment phase, followed by maintenance treatment according to the study protocol.
Median overall survival was 19.3 months with the four-drug regimen compared with 11.9 months with etoposide-carboplatin chemotherapy alone. The hazard ratio for death was 0.61, indicating a substantial reduction in mortality risk in the study population.
The results suggest that controlling tumor blood-vessel signaling may enhance the effectiveness of immunochemotherapy in this aggressive cancer.
However, this is an intensive treatment regimen.
Grade 3 or higher treatment-related adverse events occurred in more than 90% of patients receiving the full combination in the phase III trial. Careful selection and monitoring are therefore essential.
Potential candidates generally include patients with:
- Newly diagnosed extensive-stage small cell lung cancer
- Good performance status
- Adequate bone-marrow, liver and kidney function
- Acceptable cardiovascular status for anti-angiogenic therapy
Treatment requires regular blood counts, blood-pressure monitoring, imaging and assessment for both chemotherapy toxicity and immune-related adverse events.
This regimen is particularly interesting because it moves beyond the now-familiar model of “immunotherapy plus chemotherapy” by adding a third biological strategy: inhibition of tumor angiogenesis.
For international patients, its actual availability and regulatory status should be confirmed at the treating hospital before travel. Where the regimen is not approved for routine use, access may be limited to specific clinical protocols or specialist centers.
